Korea To Toughen Co-Bioequivalence Study System Amid Generic Quality Issue
Revised Pharma Act Clears First Parliamentary Hurdle
Executive Summary
Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.
You may also be interested in...
Binex Quality Issues Suggest Bigger Generic Problems In Korea?
A slew of recent manufacturing issues at several Korean pharma firms have prompted calls for improved quality control at and a change in the country's co-bioequivalence study system for generics.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.